戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  spread to the peritoneal cavity (peritoneal carcinomatosis).
2 cks metastatic disease, including peritoneal carcinomatosis.
3 s may be applied in patients with peritoneal carcinomatosis.
4  life expectancy of patients with peritoneal carcinomatosis.
5  safety of methylnaltrexone in patients with carcinomatosis.
6 l in a syngeneic model of ovarian peritoneal carcinomatosis.
7  highly effective way to suppress peritoneal carcinomatosis.
8  the therapeutic index of IPC for peritoneal carcinomatosis.
9 d complement the diagnosis of leptomeningeal carcinomatosis.
10 esophageal cancer reduced LRR and peritoneal carcinomatosis.
11 tation, which invariably involves peritoneal carcinomatosis.
12 mmunotherapy" in a mouse model of peritoneal carcinomatosis.
13 to benefit selected patients with peritoneal carcinomatosis.
14 Cs) and their capacity to initiate an active carcinomatosis.
15 l tumor excision in patients with peritoneal carcinomatosis.
16 al cavity in a condition known as peritoneal carcinomatosis.
17 results in selected patients with peritoneal carcinomatosis.
18 e (median age 55, range 4-88) had peritoneal carcinomatosis.
19 operable bowel obstruction due to peritoneal carcinomatosis.
20 d has shown clinical promise against ovarian carcinomatosis.
21 eports of high rates of local recurrence and carcinomatosis.
22 aggressive mammary cancer-induced peritoneal carcinomatosis.
23 setting of hepatic metastases and peritoneal carcinomatosis.
24 ntional imaging in the staging of peritoneal carcinomatosis.
25 and the subsequent development of peritoneal carcinomatosis.
26  (SW620) were used as a model for peritoneal carcinomatosis.
27  and treating human patients with peritoneal carcinomatosis.
28 for the diagnosis or treatment of peritoneal carcinomatosis.
29 ents with portal hypertension and peritoneal carcinomatosis.
30 calcified benign pleural lesions and pleural carcinomatosis.
31 pproach for patients with ovarian peritoneal carcinomatosis.
32 e model of aggressive GAC-derived peritoneal carcinomatosis.
33  patients with cancer with confirmed pleural carcinomatosis and 40 patients with benign pleural lesio
34 mechanisms that drive HER2(+) leptomeningeal carcinomatosis and demonstrates the efficacy of anti-GMC
35          Patient 2 presented with peritoneal carcinomatosis and died after palliative surgery.
36 ritoneal cavity is referred to as peritoneal carcinomatosis and has a very poor prognosis.
37  mortality rates in subjects with peritoneal carcinomatosis and liver metastasis were noted.
38 were invasive, and mice developed peritoneal carcinomatosis and lung metastases.
39 efinements of anatomical factors (peritoneal carcinomatosis and lymph node metastasis).
40 errantly activated Stat3 signaling in breast carcinomatosis and malignancies.
41 orrelated with cancer recurrence, peritoneal carcinomatosis and poor patient prognosis.
42 trast MR imaging enabled better detection of carcinomatosis and tumors less than 1 cm in diameter (75
43 strating the presence of mucinous peritoneal carcinomatosis and were not considered candidates for co
44 or radiation therapy, evidence of peritoneal carcinomatosis, and complications.
45 stage-dependent local recurrence, peritoneal carcinomatosis, and lung metastasis.
46 for "nonclassical" indications (peritonitis, carcinomatosis, and so on) (P < 0.0001).
47 xenograft model of ovarian cancer peritoneal carcinomatosis are provided: silencing the Rev3l subunit
48  As in human SEOC, mice developed peritoneal carcinomatosis, ascites, and distant metastases.
49 tients, one patient was found with extensive carcinomatosis at the time of laparoscopy and had no sur
50 mic chemotherapy on patients with colorectal carcinomatosis before a curative procedure.
51 an cancer frequently present with peritoneal carcinomatosis, but the mechanisms that induce naive per
52                                   Peritoneal carcinomatosis can be difficult to diagnose, as CT is in
53 e survival data for patients with peritoneal carcinomatosis colorectal cancer (pcCRC).
54 nei (PMP) is an uncommon peritoneal mucinous carcinomatosis confined to the peritoneal cavity.
55  breast cancer diagnosed with leptomeningeal carcinomatosis, CSF samples were subjected to a two-step
56 ctory OIC in cancer patients with peritoneal carcinomatosis due to low risk of complications.
57 ely contraindicated in those with peritoneal carcinomatosis due to theoretical risk and reported case
58  after complete CRS of colorectal peritoneal carcinomatosis, followed by IPC, in selected patients is
59 R) from 34% to 14% (P < .001) and peritoneal carcinomatosis from 14% to 4% (P < .001).
60  malignant bowel obstruction from peritoneal carcinomatosis from any primary malignant neoplasm and e
61 motherapy alone, the treatment of peritoneal carcinomatosis from colorectal cancer (CRPC) is still a
62                                 In the past, carcinomatosis from colorectal cancer was determined to
63 al chemotherapy for patients with peritoneal carcinomatosis from colorectal carcinoma remains to be e
64 ed with systemic chemotherapy for peritoneal carcinomatosis from colorectal carcinoma.
65                HER2(+) breast leptomeningeal carcinomatosis (HER2(+) LC) occurs when tumor cells spre
66             In models of TNBC leptomeningeal carcinomatosis, ICV dosing of hiNeuroS-TRAIL therapy sig
67 rosarcoma, and in a model of intraperitoneal carcinomatosis, imaging of CJ215 with ambient light allo
68 y, leading to significant suppression of the carcinomatosis in both animal models.
69 ole of (18)F-FDG PET in detecting peritoneal carcinomatosis in patients with stomach, ovarian, and ad
70                               The Peritoneal Carcinomatosis Index (PCI) is a scale used to assess the
71 nder, age, elevated tumor makers, peritoneal carcinomatosis index, and tumor grade influenced OS.
72           Elevated tumor markers, peritoneal carcinomatosis index, gastrectomy, and tumor grade were
73 ods of quantifying tumour burden (peritoneal carcinomatosis index, PCI), and criteria for unresectabi
74          In all, 80 patients with peritoneal carcinomatosis, inoperable malignant digestive obstructi
75                                   Peritoneal carcinomatosis is a common presentation in patients with
76                                   Peritoneal carcinomatosis is a major source of morbidity and mortal
77                      Although leptomeningeal carcinomatosis is a well-established clinical syndrome,
78  the sensitivity of both in the detection of carcinomatosis is limited.
79       Besides hepatic metastasis, peritoneal carcinomatosis is the major cause of death in Union for
80                               Leptomeningeal carcinomatosis (LC) occurs when tumor cells spread to th
81                                    Meningeal carcinomatosis (MC) is a rare complication associated wi
82 rn of metastasis corresponds to lymphangitic carcinomatosis metastatic phenotype in human cancer pati
83 -guided light dosimetry (FGLD) in peritoneal carcinomatosis mouse models.
84 e (LMD), encompassing entities of 'meningeal carcinomatosis', neoplastic meningitis' and 'leukaemic/l
85                                   Peritoneal carcinomatosis occurred more frequently in those with bi
86 urface malignancies and no gross evidence of carcinomatosis on the computed tomographic scan were enr
87 to open surgery without an increased risk of carcinomatosis or port site recurrence.
88                      Treatment of peritoneal carcinomatosis (PC) and breast cancer mice with VDA comb
89 e-cell transcriptome profiling of peritoneal carcinomatosis (PC) from 15 patients with gastric adenoc
90                                   Peritoneal carcinomatosis (PC) from colorectal cancer may be treate
91 r cytoreductive surgery (CRS) for peritoneal carcinomatosis (PC) in a tertiary center.
92                                   Peritoneal carcinomatosis (PC) is resistant to current therapies an
93                                   Peritoneal carcinomatosis (PC) is the spread of a tumour in the per
94 of the radiological extent of the peritoneal carcinomatosis (PC) or the clinical examination; and sec
95     Ascites fluid consistent with peritoneal carcinomatosis (PC) was most common, 150/241 (62%), foll
96  (LM) in patients with colorectal peritoneal carcinomatosis (PC) who underwent complete cytoreductive
97 ve anti-cancer strategy targeting peritoneal carcinomatosis (PC).
98 ould be feasible in patients with peritoneal carcinomatosis (PC).
99 eal cavity - a condition known as peritoneal carcinomatosis (PC).
100 s have a residual risk to develop peritoneal carcinomatosis (PC).
101 n EOC SKOV3 xenografts growing as peritoneal carcinomatosis (PC).
102  for the diagnosis of pulmonary lymphangitic carcinomatosis (PLC).
103 peritoneum, resulting in peritoneal mucinous carcinomatosis (PMC).
104 py treatment (P < .001), peritoneal mucinous carcinomatosis (PMCA) histopathologic subtype (P < .001)
105 nt ovarian cancer (OC) or primary peritoneal carcinomatosis (PPC).
106 dy to evaluate the outcomes of patients with carcinomatosis receiving methylnaltrexone and the first
107 ients, 18.4%) was associated with peritoneal carcinomatosis (RR: 5.9; 95% CI: 3.8, 9.2; P = .03).
108 h which SPARC ameliorates peritoneal ovarian carcinomatosis seems to be multifaceted and has yet to b
109 tients which were classified as lymphangitic carcinomatosis showed high levels of VEGF-C expression i
110 uzumab treatment of patients with peritoneal carcinomatosis showed little agent-related toxicity, con
111  local recurrence, port site recurrence, and carcinomatosis that can occur with these aggressive tumo
112 st that SPARC ameliorates ovarian peritoneal carcinomatosis through abrogation of the initial steps o
113                          In mice, peritoneal carcinomatosis use C57Bl/6 was induced in C57Bl/6 by int
114 ive and qualitative determination of pleural carcinomatosis versus noncalcified benign pleural lesion
115                     Bandicoot papillomatosis carcinomatosis virus type 1 (BPCV1) is associated with p
116  to mouse ovaries and establishes peritoneal carcinomatosis, was used to evaluate the cooperative eff
117 ice), ascites production and intraperitoneal carcinomatosis were detected 3 to 7 weeks after SKOV-3 i
118 fied by lymph node metastasis and peritoneal carcinomatosis, which are common in iCCA.
119 ame from the National Registry of Peritoneal Carcinomatosis, which includes 27 Spanish specialized pe
120                                   Peritoneal carcinomatosis, which is the most common malignant proce
121 g intravenously) to patients with peritoneal carcinomatosis who had failed standard therapies.
122          The sensitivities to depict pleural carcinomatosis with spectral reconstructions versus conv
123 ainst p53-deficient nude mouse-human ovarian carcinomatosis xenografts.

 
Page Top